PROTALIX生物療法 PLX 深 滬
已收盤 04-02 16:00:00 美东时间
2.15
-0.040
-1.83%
華盛通- 最 高2.16
- 今 開2.15
- 成交量 110.03万股
- 最 低 2.0731
- 昨 收 2.19
- 總市值 1.73亿
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 1.32
- 委 比 6.76%
- 總股本 8057.16万
- 歷史最高 77.00
- 量 比 1.20
- 振 幅 3.97%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q4 2025 Management View Dror Bashan, President and CEO, announced that the European Commission approved the 2 milligram per kilogram every 4-week...
03-18 22:13
Earnings Scheduled For March 18, 2026
Companies Reporting Before The Bell • SailPoint (NASDAQ:SAIL) is estimated to r...
03-18 19:11
Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi
Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet need. The
03-18 19:01
Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.04 by 250 percent. This is a 166.67 percent decrease over earnings of $0.09 per share
03-18 18:57
Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million
Protalix BioTherapeutics FY 2025 R&D expenses rose 51% to USD 19.57 million as net loss totaled USD 6.6 million Protalix published a press release with full-year fiscal 2025 financial and business results. Revenues from selling goods were USD 51.8 million, down 2%, driven mainly by lower sales to Ch
03-18 18:50
Protalix BioTherapeutics FY Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce FY earnings results on Wednesday, March 18th, before market open.The consensus EPS Estimate is -$0.01 (-125.0% Y/Y) and the consensus Revenue Es...
03-18 03:24
Protalix BioTherapeutics to report fiscal 2025 results and host conference call
Protalix BioTherapeutics to report fiscal 2025 results and host conference call Protalix will release fiscal year 2025 financial results and provide a business update on March 18, 2026. Management will host a conference call and webcast at 8:00 a.m. EDT on March 18, 2026, with a “Call me” option at
03-11 18:50
Protalix Gains EU Approval for Extended Elfabrio Dosing
Protalix ( ($PLX) ) just unveiled an update. On March 9, 2026, Protalix BioTher...
03-09 20:25
BRIEF-EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
BRIEF-EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio March 9 (Reuters) - Protalix Biotherapeutics Inc PBDA.F : CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS ANNOUNCE EUROPEAN COMMISSION APPROVAL OF ADDITIONAL DOSING REGIMEN OF EVERY FOUR WEEKS FOR ELFABRIO® (PEGUNI
03-09 19:04
